This presentation outlines Broad Clinical Labs' successful evaluation of the novel SPX sequencing technology, highlighting its application for rapid whole genome sequencing (WGS) in the Neonatal Intensive Care Unit (NICU). Broad, serving as an early access partner, tested the SPX system's promised high data output, accuracy, and speed. The speaker emphasizes the critical benefits of accelerated NICU WGS, including improved patient outcomes, reduced hospital stays, and significant healthcare cost efficiencies. Initial in-house validation demonstrated exceptional F1 scores for SNVs and indels, outstanding homopolymer performance, and the reliable detection of complex variants such as single-base deletions, copy number variants, and STR repeat expansions in both cell lines and diagnosed patient samples. The SPX data seamlessly integrated into a tertiary analysis platform, with AI successfully prioritizing causative variants without prior training. Impressively, Broad Clinical Labs achieved a patient-to-diagnosis time of 6 hours and 25 minutes within just six weeks of instrument installation, underscoring the technology's profound potential for transformative clinical diagnostics.
Summary:
0:00 Broad Clinical Labs' Role: Broad Clinical Labs, an integral part of the Broad Institute, focuses on genomic exploration, resource building, and clinical translation, and is uniquely positioned to test and provide real-time feedback on alpha-release platforms like the SPX technology.
1:45 Initial Attraction to SPX: Broad was drawn to the SPX technology for its potential to generate large amounts of data, high purported accuracy, and remarkable speed, envisioning its use in rapid whole genome sequencing.
2:28 Key Application: Rapid NICU Whole Genome Sequencing (WGS): The rapid capabilities of SPX are particularly beneficial for diagnosing genetic conditions in critically ill newborns in the NICU, a field pioneered by researchers like Stephen Kingsmore.
Significantly improves patient care with a diagnostic rate exceeding 50%.
Leads to shorter NICU stays, freeing up valuable hospital beds.
Offers substantial health economic advantages by reducing overall treatment costs for hospitals and insurers.
4:36 Optimizing Workflow for Speed: Broad's strategy involves meticulously optimizing each step of the sequencing process, including library preparation, synthesis, sequencing run times, and variant calling, to maximize speed.
5:24 Rapid Installation and Impressive Initial Data: The SPX instrument was installed in January and produced data within a single day. Initial runs yielded high genome coverage and "extremely impressive" F1 scores for single nucleotide variants (SNVs) and indels.
6:19 Robust Variant Detection Performance: The SPX system demonstrated strong performance across various variant types, notably achieving "fantastic" homopolymer accuracy (a common challenge for other sequencing methods), and excellent results in high/low GC regions and for indels.
7:16 Validation with Causative Variants: Beyond standard benchmarks, Broad successfully identified known causative variants in cell lines and previously diagnosed patient samples, including:
A single base deletion linked to propionic acidemia.
A 28 KB duplication in the DMD gene for Duchenne muscular dystrophy.
A full mutation in the FMR1 gene associated with Fragile X syndrome.
10:35 Seamless Integration with Tertiary Analysis: SPX data was successfully processed by a tertiary analysis platform (Fabric Genomics Fabric Enterprise), with its AI prioritizing causative variants (e.g., for propionic acidemia) without any specific pre-training for SPX output.
11:26 Achieving Accelerated Diagnosis Times: Within six weeks of instrument installation, Broad achieved a patient-to-diagnosis time of 6 hours and 25 minutes, showcasing the SPX technology's significant potential to surpass existing rapid WGS records.